$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
HER2阳性乳腺癌药物:来那替尼
2025-10-19 11:44:20
Check Details
乳腺癌用药帕博西尼的生存期和作用机制解析
2025-10-19 11:44:20
Check Details
艾拉司群(elacestrant)的功效与作用和用法用量
2025-10-19 11:44:20
Check Details
艾拉司群(elacestrant)治疗乳腺癌的疗效
2025-10-19 11:44:20
Check Details
艾拉司群治疗乳腺癌的疗效分析
2025-10-19 11:44:20
Check Details
内分泌治疗乳腺癌的新药:艾拉司群
2025-10-19 11:44:20
Check Details
艾拉司群和氟维司群相比哪个更好
2025-10-19 11:44:20
Check Details
艾拉司群的使用说明:适应症、药理作用、治疗效果
2025-10-19 11:44:20
Check Details
艾拉司群治疗乳腺癌的作用机制及上市情况详解
2025-10-19 11:44:20
Check Details
乳腺癌药物阿那曲唑的作用效果和用药注意事项概述
2025-10-19 11:44:20
Check Details
乳腺癌药物阿培利司的注意事项和治疗效果详解
2025-10-19 11:44:20
Check Details
乳腺癌药物他拉唑帕尼的治疗效果和注意事项概述
2025-10-19 11:44:20
Check Details
1
2
...
2070
2071
2072
2073
2074
2075
2076
...
4159
4160
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Sotorasib (Lumakras): A Comprehensive Guide to the First KRAS G12C-Targeted Inhibitor
2
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
3
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
4
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
5
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
6
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment
7
Lapatinib: A Targeted Anticancer Agent — Not Merely Symptom Relief
8
Lapatinib: Proper Administration Guide and Key Precautions
9
Capivasertib (Truqap) Complete Medication Guide: Indications, Dosing, Safety, and Precautions
10
Cemiplimab Storage and Handling Guide
11
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
12
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring